REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-Old Children
This study has been completed.
Sponsor:
Sanofi Pasteur MSD
Information provided by:
Sanofi Pasteur MSD
ClinicalTrials.gov Identifier:
NCT00447525
First received: March 12, 2007
Last updated: April 3, 2009
Last verified: April 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary objective:
To demonstrate the non inferiority between REVAXIS® and DT Polio® when given as a second booster to healthy 6 year-old children .
Secondary objectives:
- Additional immunogenicity assessments.
- To describe the safety profile of a single dose of REVAXIS® or DT-Polio®
| Condition | Intervention | Phase |
|---|---|---|
|
Diphtheria Tetanus Poliomyelitis |
Biological: REVAXIS® Biological: DT-Polio® |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Comparison of the Immunogenicity and Safety of a Combined Adsorbed Low Dose Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (REVAXIS®) With a Combined Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (DT Polio®) When Given as a Booster Dose at 6 Years of Age |
Resource links provided by NLM:
Further study details as provided by Sanofi Pasteur MSD:
| Estimated Enrollment: | 734 |
| Study Start Date: | February 2007 |
| Study Completion Date: | January 2008 |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Biological: REVAXIS® |
| Active Comparator: 2 | Biological: DT-Polio® |
Eligibility| Ages Eligible for Study: | 6 Years to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy child without chronic severe disease of either gender,
- 6 year-old child on vaccination day,
- Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months),
- Consent form signed by both parents, or by the legal representative, properly informed about the study.
Exclusion Criteria:
- Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine,
- Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis,
- Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study,
- Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,
- Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products,
- Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B,
- Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,
- Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus,
- Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection,
- Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00447525
Show 64 Study Locations
Show 64 Study LocationsSponsors and Collaborators
Sanofi Pasteur MSD
Investigators
| Study Director: | Anne FIQUET, MD | SPMSD |
More Information
No publications provided by Sanofi Pasteur MSD
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Anne FIQUET MD, Sanofi Pasteur MSD |
| ClinicalTrials.gov Identifier: | NCT00447525 History of Changes |
| Other Study ID Numbers: | F05-TdI-301 |
| Study First Received: | March 12, 2007 |
| Last Updated: | April 3, 2009 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Sanofi Pasteur MSD:
|
Prevention of : Diphtheria, Tetanus and Poliomyelitis |
Additional relevant MeSH terms:
|
Diphtheria Poliomyelitis Tetanus Tetany Corynebacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Myelitis Central Nervous System Viral Diseases Virus Diseases Enterovirus Infections Picornaviridae Infections |
RNA Virus Infections Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Spinal Cord Diseases Neuromuscular Diseases Clostridium Infections Neuromuscular Manifestations Neurologic Manifestations Hypocalcemia Calcium Metabolism Disorders Metabolic Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013